Stabilizing protein formulations during air-jet nebulization

International Journal of Pharmaceutics

Volumn 402, Issue 1-2, 2010, Pages 140-145

  Albasarah, Yacoub Y ^a   Somavarapu, Satyanarayana ^a   Taylor, Kevin M G ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chitosan; Impinger; Jet nebulizer; Lactate dehydrogenase; Polysorbate; Protein; Pulmonary delivery; Tween 80

Indexed keywords

CHITOSAN; LACTATE DEHYDROGENASE; NONIONIC SURFACTANT; POLYSORBATE 80;

AEROSOL; ARTICLE; ENZYME ACTIVITY; NEBULIZATION; PRIORITY JOURNAL; PROTEIN STABILITY; ZETA POTENTIAL;

AEROSOLS; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; L-LACTATE DEHYDROGENASE; MOLECULAR WEIGHT; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POLYSORBATES; SURFACE-ACTIVE AGENTS;

EID: 78349308280     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.09.042     Document Type: Article

References (57)

1. Acosta E.J., Policiva Z., Dang A., Hair M.L., Neumann A.W. Restoring the charge and surface activity of bovine lung extract surfactants with cationic and anionic polysaccharides. Biochim. Biophys. Acta 2010, 1798:882-890.
2. Adjei A.L., Gupta P.K. Pulmonary delivery of therapeutic peptides and proteins. J. Control. Release 1994, 29:361-373.
3. Alpar O.H., Somavarapu S., Atuah N.K., Bramwell W.V. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 2005, 57:411-430.
4. Amidi M., Pellikaan H.C., de Boer A.H., Crommelin D.J.A., Hennink W.E., Jiskoot W. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur. J. Pharm. Biopharm. 2008, 68:191-200.
5. Amidi M., Mastrobattista E., Jiskoot W., Hennink W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 2010, 62:59-82.
6. Andrews A.T. Partial denaturation and renaturation of β-lactoglobulin at air-water interfaces. Biochem. Soc. Trans. 1991, 272S:19.
7. Birchall J.C., Kellaway I.W., Gumbelton M. Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. Int. J. Pharm. 2000, 197:221-231.
8. Bridges P.A., Taylor K.M.G. Factors influencing the jet nebulization of liposomes. Int. J. Pharm. 2000, 204:69-79.
9. Byron P.R. Determinants of drugs and polypeptides bio-availability from aerosols delivered to the lung. Adv. Drug Deliv. Rev. 1990, 5:107-132.
10. Charm S.E., Wong B.L. Enzymatic inactivation and shearing. Biotechnol. Bioeng. 1970, 12:1103-1109.
11. Cheng Y.H., Dyer A.M., Jabbal-Gill I., Hinchcliffe M., Nankervis R., Smith A., Watts P. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. Pharm. Sci. 2005, 26:9-15.
12. Cipolla D.C., Clark A.R., Chan H.K., Gonda I., Shire S.J. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. S.T.P. Pharm. Sci. 1994, 4:50-62.
13. Coldrons V., Vanderbist F., Vanbeeck R.K., Arras M., Lison D., Preat V., Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powder in rats. J. Pharm. Sci. 2003, 92:848-938.
14. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticles characteristics on aerosol features. J. Control. Release 2003, 86:131-144.
15. Douglas K.L., Piccirillo C.A., Tabrizian M. Effect of alginate inclusion on the vector properties of chitosan-based nanoparticles. J. Control. Release 2006, 115:354-361.
16. Fangmark I., Carpin J.C. Protein nebulization. J. Aerosol Sci. 1996, 1:S231-S232.
17. Flament M.P., Leterme P., Burnouf T., Gayot A.T. Evaluation of the effectiveness of different antifoams for an alpha P1 solution. Int. J. Pharm. 1997, 156:211-217.
18. Gang Q., Wang T. Chitosan nanoparticles as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surf. 2007, 59:24-34.
19. Geng X., Kwon O.H., Jang J. Electrospinning of chitosan dissolved in concentrated acetic acid solution. Biomaterials 2005, 26:5427-5432.
20. Gilbert B.E., Knight V. Pulmonary delivery of antiviral drugs in liposome aerosols. Sem. Pediatr. Infect. Dis. 1996, 7:148-154.
21. Grenha A., Grainger C.I., Dailey L.A., Seijo B., Martin G.P., Remunan-Lopez C., Forbes B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur. J. Pharm. Sci. 2007, 31:73-84.
22. Groneberg D.A., Witt C., Wagner U., Chung K.F., Fischer A. Fundamentals of pulmonary drug delivery. Respir. Med. 2003, 97:382-387.
23. Hardy J.G., Chadwick T.S. Sustained release drug delivery to the lungs: an option for the future. Clin. Pharmacokinet. 2000, 39:1-4.
24. Harris E.L.V., Angel S. Protein Purification Methods. A Practical Approach 1989, Oxford University Press Inc., New York.
25. Hillgren A., Evertsson H., Alden M. Interaction between lactate dehydrogenase and Tween 80 in aqueous solution. Pharm. Res. 2002, 19:505-510.
26. Huang Y., Wang C. Pulmonary delivery of insulin by liposomal carriers. J. Control. Release 2006, 113:9-14.
27. Hussain A., Arnold J.J., Khan M.A., Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 2004, 94:15-24.
28. Kanaoka E., Nagat S., Hirano K. Stabilization of aerosolized IFN-gamma by liposomes. Int. J. Pharm. 1999, 188:165-172.
29. Kawashima Y., Yamamoto H., Takeuchi H., Fujioka S., Hino T. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycaemic effect. J. Control. Release 1999, 62:279-287.
30. Khatri L., Taylor K.M.G., Craig D.Q.M., Palin K. An assessment of jet and ultrasonic nebulizers for the delivery of lactate dehydrogenase solutions. Int. J. Pharm. 2001, 227:121-131.
31. Kleemann E., Dailey L.A., Abdelhady H.G., Gessler T., Schmehl T., Roberts C.J., Davies M.C., Seeger W., Kissel T. Modified polyethylene as non-viral gene delivery systems for aerosol gene therapy: investigations of the complex structure and stability during air-jet and ultrasonic nebulization. J. Control. Release 2004, 100:437-450.
32. Kumar T.R., Soppimath K., Nachaegari S.K. Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol. 2006, 7:261-276.
33. Lai S.K., Wang Y.-Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
34. Lentz Y.K., Worden L.R., Anchordoquy T.J., Lengsfeld C.S. Effect of jet nebulization on DNA: identifying the dominant degradation mechanism and mitigation methods. J. Aerosol Sci. 2005, 36:973-990.
35. Liu J., Gong T., Fu H., Wang C., Wang X., Chen Q., Zhang Q., He Q., Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 2008, 356:333-344.
36. Malik D.K., Baboota S., Ahuja A., Hasan S., Ali J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 2007, 4:141-151.
37. Martinac A., Filipovic-Grcic J., Vionovich D., Perissuti B., Franceschinis E. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int. J. Pharm. 2005, 291:69-77.
38. McCallion O.N.M., Taylor K.M.G., Thomas M., Taylor A.J. The influence of surface tension on aerosols produced by medical nebulizers. Int. J. Pharm. 1996, 129:123-136.
39. Niven R.W., Brain J.D. Some functional aspects of air-jet nebulizers. Int. J. Pharm. 1994, 104:73-85.
40. Niven R.W., Ip A.Y., Mittelman S.D., Ferrar C., Arakawa T., Prestrelski S.J. Protein nebulization. I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization. Int. J. Pharm. 1994, 109:17-26.
41. Niven R.W., Prestrelski S.J., Treuheit M.J., Ip A.Y., Arakawa T. Protein nebulization II. Stabilization of G-CSF to air-jet nebulization and the role of protectants. Int. J. Pharm. 1996, 127:191-201.
42. Patlolla R.R., Chougule M., Patel A.R., Jackson T., Tata P.N.V., Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release 2010, 10.1016/j.jconrel.2010.02.006.
43. Patton J.S. Mechanisms of macromolecules absorption by the lungs. Adv. Drug Deliv. Rev. 1996, 19:3-36.
44. Pepic I., Filipovic-Grcic J., Jalsenjak I. Colloids Surf. A: Physicochem. Eng. Aspects 2008, 327:95-102.
45. Phipps P.R., Gonda I. Droplets produced by medical nebulizers: some factors affecting their size and solute concentration. Chest 1990, 97:1327-1332.
46. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 392:1-19.
47. Rudolph C., Muller R.H., Rosenecker J. Jet nebulization of PEI/DNA polyplexes: physical stability and in vitro gene delivery efficiency. J. Gene Med. 2002, 4:66-74.
48. Schulz P.C., Rodriguez M.S., Del Blanco L.F., Pistonesi M., Agull E. Colloids Polym. Sci. 1998, 276:1159-1165.
49. Steckel H., Eskandar F., Witthons K. The effect of formulation variable on the stability of nebulized aviscumine. Int. J. Pharm. 2003, 257:181-194.
50. Takeuchi H., Yamamoto H., Kawashima Y. Mucoadhesive nanoparticulate system for peptide drug delivery. Adv. Drug Deliv. Rev. 2001, 47:39-54.
51. Tan M.L., Choong P.F.M., Dass C.R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010, 31:184-193.
52. Taylor K.M.G. Pulmonary drug delivery. Aulton's Pharmaceutics: The Design and Manufacture of Medicines 2007, 539-554. Churchill Livingstone, Edinburgh. 3rd edition. M.E. Aulton (Ed.).
53. Ten R.M., Anderson P.M., Zein N.N., Temesgen Z., Clawson M.L., Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int. Immunopharmacol. 2002, 2:333-344.
54. Thanoo B.C., Sunny M.C., Jayakrishnan A. Cross-linked chitosan microspheres: preparation and evaluation as a matrix for controlled release of pharmaceuticals. J. Pharm. Pharmacol. 1992, 44:283-286.
55. Wang W., Wang Y.J., Wang D.Q. Dual effects of Tween 80 on protein stability. Int. J. Pharm. 2008, 374:31-38.
56. Wroblewski F., LaDue J.S. Lactic dehydrogenase activity in blood. Proc. Soc. Exp. Biol. Med. 1955, 90:210-214.
57. Yamada K., Odomi M., Okada N., Fujita T., Yamamoto A. Chitosan oligomers as potential and safe absorption enhancers for improving the pulmonary absorption of interferon in rats. J. Pharm. Sci. 2005, 94:2432-2440.